New Public-Private Partnership Will Halve the Cost of Long-Lasting Contraceptive Implant for World's Poorest
This week, MSD, the Bill & Melinda Gates Foundation, and other global health leaders took a step toward fulfilling commitments made at the London Summit on Family Planning by announcing a new public-private partnership to increase access to long-acting contraceptive implants in some of the world’s poorest countries.
MSD has generously agreed to halve the cost of IMPLANON and its next generation implant, IMPLANON NXT, for supply through reproductive health projects in select developing countries throughout the next six years. IMPLANON is a single-rod, long-acting, and reversible contraceptive implant that offers women three years of pregnancy protection. The implants are pre-packaged and fully sterilized, both advantageous features for working in settings with limited health care infrastructure.
The announcement comes just weeks after a similar agreement between Bayer HealthCare AG and the Bill & Melinda Gates Foundation regarding the long-acting implant Jadelle. Pathfinder is thrilled to see this continued emphasis on commitments made in London last summer, particularly as it pertains to improving access to reproductive health services for the world’s 222 million women who currently want, but lack access to modern methods of contraception. It is our hope that these innovative new partnerships will inspire additional support for reproductive health care and services that contribute to stronger, healthier women and communities worldwide.
Please contact Kate Stookey, Director of Public Affairs, at 617-972-1231 or email@example.com
Pathfinder joins the global health community in celebrating World Contraception Day. Launched in 2007, World Contraception Day aims to raise awareness about the importance and availability of a full range of contraception, especially for young people.
Today, Pathfinder celebrates Global Female Condom Day with educational events and advocacy around the world that brings a heightened focus on a still-obscure tool in women’s sexual and reproductive health.